v3.25.2
DEBT - Additional Information (Details)
6 Months Ended
Nov. 01, 2024
USD ($)
Jun. 30, 2025
Minimum    
Debt Instrument [Line Items]    
Royalty payment, ratio   1.65
Maximum    
Debt Instrument [Line Items]    
Royalty payment, ratio   2.0
Pharmakon Loan Agreement | Tranche A    
Debt Instrument [Line Items]    
Maximum borrowing capacity under term loan $ 125,000,000  
Effective interest rate 10.32%  
Pharmakon Loan Agreement | Tranche B    
Debt Instrument [Line Items]    
Maximum borrowing capacity under term loan $ 75,000,000  
Pharmakon Loan Agreement | Tranche C    
Debt Instrument [Line Items]    
Maximum borrowing capacity under term loan $ 50,000,000  
Pharmakon Loan Agreement | Term Loans    
Debt Instrument [Line Items]    
Percentage added to prime rate for debt instrument interest rate 5.75%  
Debt instrument, variable interest rate, type flag Secured Overnight Financing Rate (SOFR) [Member]  
Floor rate 3.00%  
Percentage of commitment amount to fund loan 2.50%  
Pharmakon Loan Agreement | Term Loans | Prepaid Prior To Third Anniversary Of Funding Date    
Debt Instrument [Line Items]    
Prepayment premium on percentage of term loan 3.00%  
Pharmakon Loan Agreement | Term Loans | 3rd Anniversary But, Prior To 4th Anniversary Of Funding Date    
Debt Instrument [Line Items]    
Prepayment premium on percentage of term loan 2.00%  
Pharmakon Loan Agreement | Term Loans | 4th Anniversary Of Funding Date    
Debt Instrument [Line Items]    
Prepayment premium on percentage of term loan 1.00%  
Royalty Pharma Revenue Participation Right Purchase Agreement    
Debt Instrument [Line Items]    
Upfront payment received $ 125,000,000  
Royalty Pharma Revenue Participation Right Purchase Agreement | Scenario One    
Debt Instrument [Line Items]    
Percentage of annual net sales 7.75%  
Royalty Pharma Revenue Participation Right Purchase Agreement | Scenario Two    
Debt Instrument [Line Items]    
Percentage of annual net sales 1.00%  
Royalty Pharma Revenue Participation Right Purchase Agreement | Minimum | Scenario Two    
Debt Instrument [Line Items]    
Revenue interest payments $ 1,000,000,000  
Royalty Pharma Revenue Participation Right Purchase Agreement | Maximum | Scenario One    
Debt Instrument [Line Items]    
Revenue interest payments $ 500,000,000  
BioPharma Credit PLC | Pharmakon Loan Agreement    
Debt Instrument [Line Items]    
Line of credit, maturity period 5 years  
Maximum borrowing capacity under term loan $ 250,000,000